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Diseases due to mutations in mitochondrial DNA probably represent the most common 
form of metabolic disorders, including cancer, as highlighted in the last years. 
Approximately 300 mtDNA alterations have been identified as the genetic cause of 
mitochondrial diseases and one-third of these alterations are located in the coding genes 
for OXPHOS proteins. Despite progress in identification of their molecular 
mechanisms, little has been done with regard to the therapy. Recently, a particular gene 
therapy approach, namely allotopic expression, has been proposed and optimized, 
although the results obtained are rather controversial. In fact, this approach consists in 
synthesis of a wild-type version of mutated OXPHOS protein in the cytosolic 
compartment and in its import into mitochondria, but the available evidence is based 
only on the partial phenotype rescue and not on the demonstration of effective 
incorporation of the functional protein into respiratory complexes. In the present study, 
we took advantage of a previously analyzed cell model bearing the m.3571insC 
mutation in MTND1 gene for the ND1 subunit of respiratory chain complex I. This 
frame-shift mutation induces in fact translation of a truncated ND1 protein then 
degraded, causing complex I disassembly, and for this reason not in competition with 
that allotopically expressed. We show here that allotopic ND1 protein is correctly 
imported into mitochondria and incorporated in complex I, promoting its proper 
assembly and  rescue of its function. This result allowed us to further confirm what we 
have previously demonstrated about the role of complex I in tumorigenesis process. 
Injection of the allotopic clone in nude mice showed indeed that the rescue of complex I 
assembly and function increases tumor growth, inducing stabilization of HIF1α, the 
master regulator of tumoral progression, and consequently its downstream gene 
expression activation.  
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MITOCHONDRIA 
Mitochondria are eukaryotic subcellular organelles which play a crucial role in the 
energetic balance of the cell, since oxidative phosphorylation takes place in these 
compartments. This implies that mitochondria have a critical position between energy 
uptake (food uptake and metabolism) and energy production, and as a consequence, 
they are involved in many other cellular process, like thermogenesis, apoptosis, oxygen 
reactive species production and calcium homeostasis. 
Mitochondria show a complex double-membrane organization, where the outer 
membrane (OM) bounds the organelle, whereas the inner membrane (IM) separates the 
matrix space from the intermembrane space. The IM is organized in distinct structures, 
the peripheral inner membrane and the cristae, defined by several lines of evidence as 
the active site of oxidative phosphorylation  (Perotti et al., 1983; D'Herde et al., 2001; 
Vogel et al., 2006), separated from peripheral inner membrane by narrow tubular 
structure called cristae junctions (Perkins et al., 2001; Frey et al., 2000). 
In the cytosol, mitochondria form a highly dynamic reticulum, whose morphology 
depends on the cell types and context, and is due to the constant fusion/fission of both 
OM and IM (Chen et al., 2004, 2005; Liu et al., 2009). The ultrastructure and reticulum 
organization are determined by mitochondria-shaping proteins that regulate the 
equilibrium between fusion and fission process (Chen H et al., 2003). 
A peculiar feature of mitochondria is the presence within the matrix of multiple copies 
of its own DNA, which encodes a small number of proteins that, with together those 
nucleus-coded ones, are essential for the energetic function (Anderson et al. 1981). In 
fact, mitochondrial function relies on the coordinate expression of two different genetic 
systems, the mitochondrial and the nuclear genome; however, it’s the latter to encode 
the majority of proteins necessary to the organelle physiology, including those 
fundamental to expression and maintenance of the mitochondrial DNA (mtDNA).  
A growing interest in mitochondria has been shown in recent years, due to implication 
of the mitochondrial dysfunction implication in human disorders. Many rare genetic 
pathologies are indeed caused by mutations in either mitochondrial DNA and nuclear 
genes that encode for mitochondrial proteins. Mitochondrial dysfunctions have been 
implicated also in more common human diseases, like neurodegenerative diseases, 
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cancers, diabetes and the natural process of ageing  (Zeviani et al., 1997; Wallace 2005; 
Mao and Holt, 2009; Trifunovic, 2006). 
 
 
The mitochondria ultrastructure 
Mitochondria are double-membrane organelles; the OM is highly permeable because it 
contains many pores for small molecules, whereas the IM is impermeable to most small 
molecules and ions. This property is required to maintain an electrochemical gradient 
between the matrix and the intermembrane space (Nicholls et al., 2002). The IM folds 
into membrane inter-digitations, called cristae (Frey and Mannella, 2000), which 
increase their surface area and mass (Fig.1) and which represent a distinct 
element/compartment extending into the mitochondrial interior like tubules or lamellae, 
and not as an unfolded membrane of the IM, as initially believed. The inner boundary 
membranes and the cristae are joined by a limited number of discrete sites called cristae 
junctions, which typically have a consistent diameter of 15-20 nm, but may be altered 
by matrix volume and respiratory activity (Frey et al., 2002; Frey and Mannella, 2000; 
Mannella et al., 1994; Mannella et al., 1997). It has been estimated that three quarters of 
the IM mass are proteins, and many of these are proteins of the oxidative 
phosphorylation (OXPHOS) system.  
The matrix, interior of IM, is composed of a gel-like substance, which contains enzymes 
of the tricarboxylic acid (TCA) cycle or the Krebs cycle (Krebs and Johnson, 1937) and 
β-oxidation. These oxidation-reduction reactions and energy transfer processes make 
mitochondria the powerhouses of eukaryotic cells (Mao and Holt, 2009). 
               
 
              
 
 
 
 
 
 
  
 
 
 
 
 
 
 
Figura 1. Mitochondria ultrastructure. (a) Computer model of mitochondrion section of chick 
cerebellum from segmented 3D tomograms. Model shows all cristae in yellow, the inner membrane 
boundary in light blue and the outer membrane in dark blue. (b) A single section
the mitochondrion used to create model in (a).
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 through 3D tomogram of 
 From Frey and Mannella, 2000. 
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Mitochondrion matrix activity: β-oxidation and tricarboxylic acid cycle 
 
Two of the most important metabolic pathways take place in the mitochondrial matrix. 
Glucose, fatty acids and amino acids are the three substrates that an organism can use to 
maintain energy homeostasis, not only for energy production but also for 
(macro)molecules biosynthesis. In particular, when glucose supply becomes limited 
(during fasting, for example), fatty acid degradation assumes a fundamental importance 
for the most of tissues. After a first hydrolysis by endothelium-bound lipases, the uptake 
by plasmatic membrane proteins and the conversion to acyl-CoAs, the further step of 
the fatty acids catabolism is the mitochondrial fatty acids β-oxidation (FAO). The 
mitochondrial membrane is impermeable to acyl-CoAs; for this reason, acyl-CoAs use 
the carnitine shuttle (CPT) for their import into mitochondria (Fig.2). CPT1 converts an 
acyl-CoA in acylcarnitine, which is translocated across the mitochondrial membrane by 
carnitine acylcarnitine translocase (CACT), exchanging a free carnitine molecule from 
the inside. CPT2, located at the inner membrane, reconverts acylcarnitines into their 
CoA esters, which can undergo FAO (van der Leij et al., 2000; Ramsay et al., 2001; 
Bonnefont et al., 2004). Once inside the mitochondria, acyl-CoAs are cleaved  into 
acetyl-CoA units via the classic series of the four enzyme reactions called β-oxidation 
(Fig.2). The pathway is a cyclic process in which acyl-CoAs are shortened, whereby the 
two carboxy-terminal carbon atoms are released as acetyl-CoA units each time a cycle 
is fully completed. First, an acyl-CoA-ester is dehydrogenated to yield a trans-2-enoyl-
CoA. This is followed by hydration of the double bond and in the third step the resulting  
L-3-hydroxy-acyl-CoA is dehydrogenated to 3-keto-acyl-CoA. Finally, thiolytic 
cleavage of  the 3-keto-acyl-CoA produces a two-carbon chain-shortened acyl-CoA plus 
acetyl-CoA. Each cycle yields an acyl-CoA shortened by two carbon atoms, an acetyl-
CoA, and one nicotinamide adenine dinucleotide (NADH) and one flavin adenine 
dinucleotide (FADH2) as electron carriers (or reducing equivalents). The resulting acyl-
CoAs enters another cycle of FAO whereas the electron carriers deliver the electrons to 
the electron transport chain and the acetyl-CoA can enter the tricarboxylic acids (TCA) 
cycle, also known as the citric acid cycle or the Krebs cycle (Krebs and Johnson, 1937). 
Indeed, the conversion of reducing power provided by carboxylic acids into the 
respiratory chain-usable reduced coenzymes NADH and FADH2 constitutes a main 
function of TCA cycle. The TCA also plays a central role in an endless series of 
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metabolic pathways, in particular thanks to transamination reactions; moreover, several 
major anaplerotic pathways require the TCA cycle breakdown of acetyl-CoA and the 
multistep interconversion of carbon skeletons.  
                         
 
 
         
           
Figura 2. Mitochondrial β-oxidation in human. After transport across the plasma membrane, fatty acids 
are activated to acyl-CoAs at the cytosolic site. CPT1 converts the acyl-CoA into an acylcarnitine, which 
is subsequently transported across the mitochondrial membrane by CACT. CPT2 converts the 
acylcarnitine back into an acyl-CoA. Long chain acyl-CoAs are metabolised by the membrane bound 
enzymes, very long chain acyl-CoA dehydrogenase (VLCAD) and mitochondrial trifunctional protein 
(MTP), which has hydratase, long chain hydroxyacyl-CoA dehydrogenase (LCHAD) and thiolase 
activity. Short and medium chain acyl-CoAs are metabolised in the mitochondrial matrix by medium 
chain acyl-CoAdehydrogenase (MCAD), short chain acyl-CoA dehydrogenase (SCAD), crotonase, 
medium and short chain hydroxyacyl-CoA dehydrogenase (M/SCHAD) and medium chain 3-ketoacyl-
CoA thiolase (MCKAT). The oxidation of unsaturated fatty acids such asoleic acid requires the action of 
an isomerase [dodecenoyl-CoA delta isomerase (DCI)]. C18 denotes an acyl-CoA with a chain length of 
18 carbon atoms, and so forth. From Houten and Wanders, 2010. 
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More important, it is also the third step in carbohydrate catabolism, after conversion of 
glycolysis-produced pyruvate in acetyl-CoA, and the following step in protein 
catabolism after cleavage of amino acids and conversion in acetyl-CoA. The TCA cycle, 
that comprises eight reactions resulting in the progressive oxidative decarboxylation of 
acetyl CoA (Fig. 3), begins with the transfer of two-carbon acetyl group from acetyl-
CoA to the four-carbon acceptor compound (oxaloacetate) to form the six-carbon 
compound citrate. The citrate then entrys into a series of chemical transformations, 
losing two carboxylic groups as CO2; most of energy made available by the oxidative 
steps is transferred to other metabolic process by GTP (or ATP) or as energy-rich 
electrons to NAD+ generating NADH (for each acetyl group that enter in the TCA 
cycle, three molecules of NADH are produced) and to FADH to generate FADH2. The 
generated NADH may later on donate its electrons to the respiratory chain complex to 
drive ATP synthesis, whereas FADH2 is covalently attached to succinate 
dehydrogenase, an enzyme functioning both in the TCA and the mitochondrial electron 
transport chain. FADH2, therefore, facilitates electrons transfer to coenzyme Q, which is 
the final acceptor of the reaction catalyzed by the succinate ubiquinone oxidoreductase 
complex, also acting as an intermediate in the electron transport chain. At the end of 
each TCA cycle, the four-carbon oxaloacetate has been regenerated to continue  the 
cycle. 
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Figure 3. The TCA cycle and related enzymes. A: the TCA cycle takes place in the mitochondrial 
matrix (A), where its enzyme components are packed as a series of metabolons directly feeding reduced 
equivalent to the respirasome insert within the mitochondrial membrane further used to generate ATP by 
the ATPasome. B: the reactions catalyzed by the several TCA cycle enzyme components, featuring the 
sites of production of  reduced  equivalent (boxed text) and including the short-circuit  within the cycle by 
the transamination reaction catalyzed by the aspartate amino transferase. 1,pyruvate dehydrogenase; 2, 
citrate synthase;3, aconitase; 4, isocitrate dehydrogenase; 5, ketoglutarate dehydrogenase; 6, succinyl-
CoA synthase; 7, succinate  dehydrogenase; 8, fumarase; 9, malate dehydrogenase; 10, aspartate amino 
transferase. ANT, adenine nucleotide translocator; im, inner membrane; RC, respiratory chain. From 
Brière JJ et al., 2006. 
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The mitochondrial membrane oxidative phosphorylation 
 
The mitochondrial IM hosts the five protein complexes of oxidative phosphorylation 
(OXPHOS): complex I (NADH dehydrogenase or NADH:ubiquinone oxidoreductase), 
complex II (succinate dehydrogenase or succinate:ubiquinone oxidoreductase), complex 
III (the bc1 complex or ubiquinone:cytochrome c oxidoreductase), complex IV          
(cytochrome c oxidase, ciclooxygenase or reduced cytochrome c: oxygen 
oxidoreductase) and complex V (ATP synthase). Additionally, OXPHOS system also 
involves two electron transport carriers: ubiquinone or coenzyme Q10 and cytochrome 
c. The  electron  transport  chain  is  coupled  to  the  generation  of  a  proton  gradient  
across  the inner  mitochondrial  membrane,  which  is  further  used  by  the  fifth  
enzymatic  complex (F 0 F 1 -ATP  synthase), to synthesize ATP from ADP and 
inorganic phosphate (Saraste, 1999) (Fig. 4).  
Complex I (NADH dehydrogenase) is the largest of the respiratory complexes, 
comprising forty-five  subunits, of which seven are mitochondrially encoded (Carroll et 
al., 2002). The enzyme contains multiple prosthetic groups, one flavomononucleotide 
(FMN) and eight iron-sulphur clusters (Carroll  et  al.,  2006). Complex I transfers 
electrons from NADH to ubiquinone (CoQ), generating ubiquinol  (CoQH2), with the 
translocation of four protons across the inner membrane into the intermembrane  space 
(Nicholls and Ferguson, 2002). Ubiquinol is also produced by complex II (succinate  
dehydrogenase), which oxidases succinate to fumarate in the Krebs cycle, and donates 
electrons to  the respiratory  chain, as written above. Complex II is the only respiratory 
enzyme completely encoded by the nucleus (Rustin et al., 2002), comprising a catalytic 
subunit, succinate dehydrogenase, and two membrane subunits, anchoring the complex 
into the mitochondrial IM (Capaldi et al.,  1977). Electrons from succinate are donated 
to the covalently bound FAD of succinate dehydrogenase, reducing it to FADH2. The 
electrons are further transported via a number of iron/sulphur clusters to CoQ, reducing 
it to CoQH2 (Lancaster and Kroger, 2000; Saraste, 1999). A  third source transferring 
electrons to generate ubiquinol is the glycerol-3-phosphate dehydrogenase enzyme.  
Ubiquinol donates its two electrons consecutively to complex III (ubiquinol cytochrome 
c oxidoreductase) (Walker et al., 1992). One electron is transferred to cytochrome c via 
the Rieske iron-sulphur protein, while the second is transferred back to the matrix side, 
to cytochrome b of complex III. Cytochrome b is able to accept two electrons, which, in 
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turn, are donated to ubiquinone at the matrix side, generating ubiquinol. Due to the 
recycling of ubiquinone this process is also termed the Q-cycle (Darrouzet et al., 2001).  
                  
 
 
 
        
Figure 4. Representation of the mitochondrial respiratory chain complexes and the oxidative 
phosphorylation system. The four complexes of the respiratory chain and the ATP synthase are 
schematized and the electron/proton pathways along these complexes are indicated. From Lemarie and 
Grimm, 2011. 
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Complex III, the middle segment of the respiratory chain, transfers two electrons from 
CoQH2 to cytochrome c, which then shuttles the electrons to complex IV (cytochrome c 
oxidase). Complex III couples electron transfer to the translocation of two protons 
across the IM. This complex has only one mtDNA-encoded subunit, cytochrome b; the 
other 10 subunits are nucleous-encoded, and at least one of these has been reported to be 
essential for the complex assembly (Berry et al., 2000; Yu et al., 1998; Zeviani et al., 
2003). Cytochrome c is a water-soluble protein that donates electrons on the 
cytoplasmic side of the mitochondrial IM to complex IV. This is the terminal 
component of the  respiratory chain, composed of 13 subunits, of which three are 
encoded by the mtDNA. Complex IV catalyzes the transfer of electrons from the 
reduced cytochrome c pool to molecular oxygen, reducing it to water. In this step, four 
electrons have to be donated from complex IV to two molecules of oxygen, without 
generating any reactive oxygen species. This is achieved by complex IV storing the  
four electrons on haem and copper atoms, before releasing them only in the presence of 
two molecules of oxygen and four protons at the matrix side of the mitochondrial IM. 
During this reaction four protons are translocated across the mitochondrial IM from the 
matrix side to the intermembrane space (Schultz and Chan, 2001).  
The energy released by the flow of electrons through the respiratory chain is used to 
pump protons through the mitochondrial inner membrane by complexes I, III, and IV. 
This electrochemical gradient is finally utilized by the ATP synthase (F1 F0 -ATPase) to 
generate ATP (Saraste, 1999). This complex is bipartite, as implied by the 
nomenclature, composed of a membrane-bound portion (F0) and a large extra-
membranous portion (F1) that protrudes into the matrix space. F1 and F0 are linked 
together by two stalks (Capaldi and Aggeker, 2002). Complex V has two subunits 
encoded by mtDNA (ATPase6 and ATPase8), that take part to the membrane-bound 
portion (F0) of the  complex, and about 13 other subunits encoded by nDNA (Abrahams 
et al., 1994). Protons from the  intermembrane space enter complex V through the F0 
complex leading to subunit rotation within the complex. The energy from this rotation is 
then used for ATP synthesis, which takes place in the F1 complex (Schultz  and Chan, 
2001). The ATP synthesized in the mitochondrial matrix is transported across the inner 
mitochondrial membrane in exchange with cytosolic ADP, through the adenine  
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nucleotide translocator (ANT), an energetically favourable reaction driven by the 
voltage gradient across the IM (Saraste, 1999). 
The knowledge about the overall organization of the five respiratory complexes is 
changed in the last decade. In fact, a fluid-state model, based on the idea that complexes 
are freely diffuse in the IM and that electron transfer is based on random collision of 
single complexes, has been replaced by a solid-state model, which propose a stable 
interaction between OXPHOS complexes within entities named supercomplexes. This 
model is now supported by a wide range of experimental findings that demonstrated a 
strict association between the respiratory complexes in mitochondria of yeast, plants 
and mammals (Schagger and Pfeiffer 2000; Krause et al, 2004; Schafer et al., 2006). 
The supramolecular organization of the OXPHOS system is considered to be of great 
functional importance. Formation of supercomplexes plays a role in the assembly and 
stability of the complexes, suggesting that the supercomplexes are the functional state of 
the respiratory chain (Vonck et al., 2009). Respiratory supercomplexes may (i) allow 
enhanced electron transfer rates by electron channeling, (ii) represent regulatory units of 
respiration, (iii) determine the ultrastructure of the inner mitochondrial  membrane, (iv) 
increase the stability of OXPHOS complexes, and (v) increase the protein insertion 
capacity of the mitochondrial IM. Several experimental observations confirm one or the 
other roles of the OXPHOS supercomplexes (Boekema et al., 2007). 
 
 
Mitochondrial DNA  
 
Mitochondria contain the only extranuclear source of DNA in animal cells (Nass, 1966).  
MtDNA is a circular, double-stranded, 16569 base pair molecule of DNA which 
encodes 37 genes, including 13 essential polypeptides for the OXPHOS system, 2 
ribosomal RNAs (12S and 16S) and 22 tRNAs (Anderson et al, 1981) (Fig. 5). The 
remaining proteins required for mitochondrial metabolism and maintenance are 
synthesized in the cytosol and are specifically targeted, sorted and imported to their 
correct mitochondrial location (Mokranjac and Neupert, 2005). The mitochondrial 
genome has unique characteristics which distinguish it from the nuclear genome; it is 
strictly maternally inherited and there are several hundred to several thousand of copies  
17 
 
 
 
 
 
 
 
 
                        Figure 5. Map of human mtDNA. From Falkenberg et al., 2007.  
 
 
 
 
 
 
 
 
 
18 
 
within a single cell. The number of copies present varies between different cell types 
depending on the energy demand within the tissue (Taylor and Turnbull, 2005). There 
are no introns and the genes have either none, or very few non-coding bases between 
them and in most cases termination codons are not present, but are created post-
transcriptionally by polyadenylation (Anderson et al., 1981). There are only two non-
coding regions in the mtDNA  and they contain most of the known regulatory functions. 
The major one is the 1 kb displacement D-loop, characterized by the presence of a triple 
strand structure, due to association of the new H-strand in this region (Fernandez-Silva 
et al., 2003). The D-loop contains the origin of H-strand DNA replication (OH) and is 
also the site of transcription from opposing heavy and light strand promoters (Clayton, 
2000; Scarpulla, 2008). The second non-coding region is about 30 nucleotides long and 
contains the origin of L-strand replication (OL). This region is located in a cluster of 
five tRNA genes around two thirds of the mtDNA length from the OH (Anderson et al., 
1981; Fernandez-Silva et al., 2003). 
The physiological polyploidy of the mitochondrial genome gives rise to a peculiar 
genetic inheritance which is dominated by the phenomena of homo- and heteroplasmy, 
the latter being the coexistence in one cell of two or even more different mitochondrial 
genotypes. It is generally accepted that as mutations may arise in one copy of the 
mtDNA, they may hence be selected against or shift to increase the mutation load 
within a cell until detrimental effects take over or a pathological phenotype sets in. This 
threshold level may vary according to the mutation type; it has been shown in 
neurodegenerative diseases that the penetrance or the severity of a condition may well 
depend on the heteroplasmy level in the individual (Carelli et al., 2002; Laloi-Michelin 
et al., 2009); it has also been demonstrated that the tumorigenic potential associated to a 
particular mitochondrial mutation reveals itself only at a exact mutation load ( Gasparre 
et al, 2011; Park et al., 2009). 
MtDNA shows a higher mutation rate than nuclear DNA (Nachman et al., 1996; 
Schriner et al., 2000) and that is due to a number of elements, among which (i) the 
proximity to reactive oxygen species production sites, (ii) the lack of protective 
histones, (iii) the highly compact structure which lacks buffering sequences such as 
introns and (iv) a less efficient DNA repairing system. 
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Another particular feature of mtDNA is the strict maternal inheritance: mtDNAs  can 
only evolve by the sequential accumulation of mutations along radiating maternal 
lineages. For this reason, if an mtDNA mutation arises that is beneficial in a particular 
environment, it and its descendants will increase in frequency in that environment. This 
results in the generation of a group of related mtDNA haplotypes (haplogroups) 
concentrated in a particular geographical region. The human mtDNA sequence is highly 
variable, and approximately one-fourth to one-third of mtDNA polypeptide and 
structural RNA sequence variants appear to be functionally important; natural selection 
then enriches for the regionally appropriate coupling efficiency and thus mtDNA 
haplogroup (Mishmar et al., 2003; Wallace et al., 2003; Ruiz-Pesini et al., 2004; Ruiz-
Pesini and Wallace, 2006). 
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MITOCHONDRIAL DISEASES 
 
Mitochondrial diseases can be caused by mutations in mitochondrial DNA and by 
mutations in nuclear DNA.  
MtDNA mutations causing diseases were first reported in 1988 (Wallace et al., 1988; 
Holt et al., 1988) and since then more than 300 pathogenic mtDNA mutations have been 
described. MtDNA genetics is very complex because mutations in different 
mitochondrial genes can give similar phenotypes, mutations in the same gene can give 
different phenotypes, and the same mtDNA mutation at different levels of heteroplasmy 
can result in very different phenotypes.  
Clinically relevant mtDNA variants fall into three classes: (i) recent deleterious  
mutations  resulting  in maternally transmitted disease, (ii) ancient adaptive variants that 
predispose individuals to disease in different environments, and (iii) the age-related 
accumulation of somatic mtDNA  mutations  that  erode function and provide the aging 
clock (Wallace, 2005). Diseases due to rearrangement mutations and base substitution 
mutations belong to the first class and they include: maternally inherited Type II 
diabetes; deafness chronic progressive external ophthalmoplegia (CPEO), Kearns–Sayre 
syndrome (KSS) associated with ophthalmoplegia, ptosis, and mitochondrial myopathy 
with ragged red fibers (RRFs) (Mita et al., 1989; Wallace et al., 2001; Wallace and Lott, 
2002; Wallace, 2005); the Pearson marrow/pancreas syndrome (Kapsa et al., 1994); 
LHON (Wallace et al., 1988); Leigh syndrome (Holt et al.,1990); mitochondrial 
myopathy (Andreu et al., 1998,1999a,b); MERRF (Wallace et al., 1988b; Shoffner et 
al., 1990); MELAS (Goto et al., 1990); encephalomyopathy; Alzheimer’s disease (AD) 
and Parkinson’s disease (PD) (Shoffner et al., 1993; Khusnutdinova et al., 2008). The 
second class (ii) of variants depends on the ancient adaptive haplogroups which still 
influence individual predisposition to a wide spectrum of common diseases today. To 
make some examples, the first evidence that mtDNA haplogroups could modify disease 
predisposition was the discovery that European haplogroup J increases penetrance of the 
milder LHON mutations (Brown et al., 1995, 1997, 2002;  Torroni et al., 1997; Ghelli et 
al., 2009). On the other hand, it has also been demonstrated that haplogroup J correlates 
also with longevity in Europeans (Ivanova et al., 1998; De Benedictis et  al., 1999; Rose 
et al., 2001) but also with a more rapid AIDS progression (Hendrickson et al., 2008). In 
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addition, mtDNA haplogroups have also been correlated with athletic performance, 
which is consistent with different mtDNA haplogroups having different mitochondrial 
ATP production competence, due to differential coupling efficiency (Scott et al., 2005, 
2009). 
About the third variant class (iii), mutations in the mtDNA have been observed to 
accumulate with  age in a variety of postmitotic tissues in a wide range of species and in 
a spectrum of complex age-related diseases (Wallace, 2005c). Increasing the mtDNA 
mutation rate in mice increases their aging rate (Trifunovic et al., 2004; Kujoth et al., 
2005), while decreasing the somatic mtDNA mutation rate by introducing catalase into 
the mitochondrial matrix extends mouse life span (Schriner et al., 2005). Therefore, the 
accumulation of somatic mtDNA mutations provides an aging clock that helps defining 
an animal’s life span and contributes to the delayed-onset and progressive course of 
complex diseases (Wallace, 2005c). Cancer is also (but not only) an age-related disease, 
and both somatic and germline mtDNA mutations have been reported in cancers 
including renal adenocarcinoma, colon cancer cells, head and neck tumors, astrocytic  
tumors, thyroid tumors, breast tumors, prostate tumors, etc. (Wallace, 2005a; Brandon 
et al., 2006) (see “Mitochondrial metabolic dysfunction and cancer” paragraph). 
Besides, mitochondrial ROS production appears to be an important component of 
carcinogenesis (Petros et al., 2005; Ishikawa et al., 2008). 
Mutations in nDNA-encoded OXPHOS genes have also been linked to a variety of 
multisystem disorders ranging from lethal childhood Leigh syndrome to predisposition 
to depression. Mutations in the structural subunits of Complexes I and II and in a 
Complex IV assembly factor, SURF1 (Zhu et al., 1998; Procaccio and Wallace, 2004), 
can cause severe OXPHOS defects and result in the lethal childhood disease, Leigh 
syndrome. Mutations in the nDNA POLG or Twinkle helicase are associated with 
multiple mtDNA deletions and have been linked to autosomal dominant or autosomal 
recessive progressive external ophthalmoplegia (PEO). POLG mutations can cause a 
broad spectrum of diseases from mild myopathy to lethal Alpers syndrome (Spelbrink et 
al., 2001; Van Goethem et al., 2001). Some ANT1 gene mutations can inactivate the 
protein and result in autosomal recessive myopathy and cardiomyopathy associated with 
multiple mtDNA deletions without PEO (Palmieri et al., 2005). However, other ANT1 
missense mutations act as dominants and cause autosomal dominant PEO, associated 
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with the accumulation of multiple mtDNA deletions (Kaukonen et al., 2000). Mutations 
in deoxyguanosine kinase and mitochondrial thymidine kinase 2 cause mtDNA 
depletion (Mandel et al., 2001; Saada et al., 2001), and mutations in succinyl-CoA 
synthase subunit SUCLA2 cause mild methylmalonic aciduria, Leigh-like 
encephalomyopathy, dystonia, and  deafness in association with mtDNA depletion  
(Carrozzo  et  al.,  2007).  Mutations  in the cytosolic thymidine phosphorylase cause 
mitochondrial neurogastrointestinal encephalomyopathy (Nishino et  al., 1999) 
associated with mtDNA deletions and depletion. Mutations in the gene encoding the 
mitochondrial fusion protein OPA1 cause autosomal dominant optic atrophy (Delettre et 
al., 2000), while mutations in mitofusin2 result in the peripheral neuropathy, Charcot-
Marie-Tooth 2 (Zuchner et al., 2004). Mitochondrial diseases can also result from 
defects in the genes for mitochondrial metabolic proteins. For example, defects in 
coenzyme Q10 metabolism  and various Krebs cycle enzyme genes have been reported 
(Wallace et al., 2007b, 2010). 
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MITOCHONDRIAL METABOLIC DYSFUNCTION AND CANCER 
 
Defects in mitochondrial function have long been suspected to contribute to the 
development and  possibly progression of cancer: in 1930, Otto Warburg proposed that 
cancer was caused by defects in OXPHOS or respiration in the mitochondria, forcing 
cells to shift to energy generation process through glycolysis, despite aerobic 
conditions. After several decades of research related to what is defined “Warburg 
effect” in tumor, during the past few years it is being reconsidered but it continues to be 
a subject of even more increasing interest in cancer research. In fact, it is becoming 
clear that it plays an important  role in tumor development by remodeling the metabolic 
profile of tumor cells, which allows cell survival under adverse conditions. Since the 
description of the Warburg effect, several studies have shown that cancer cell 
mitochondria are small, possess few cristae, have a characteristic shape and size and an 
altered membrane, but only in last decade mutations in gene encoding mitochondrial 
proteins were demonstrated to be directly involved in tumorigenesis. Like in the 
neurodegenerative diseases, both nDNA and mtDNA mutations have been found 
implicated in human cancer. In particular, three mitochondrial enzymatic functions, 
between TCA and OXPHOS, are affected by nuclear gene mutations and are involved in 
tumorigenesis process of different tumors.   
 
Nuclear genes involved in mitochondrial defects in cancer 
Mitochondrial succinate-coenzyme Q oxidoreductase or complex II of the respiratory 
chain catalyzes the conversion of succinate to fumarate in the TCA cycle and 
simultaneously transfers electrons from succinate to coenzyme Q. It is comprised of 
four nuclear-encoded subunits, SDHA, SDHB, SDHC and SDHD (Fig. 6), whose both 
germinal and somatic loss-of-function mutations have been described and appreciated in 
paragangliomas (PCC), in renal cell carcinomas (RCC) and in pancreatic cell cancers 
(PCC) (Baysal et al. 2000; Housley et al., 2010; Ricketts et al., 2008; van Nederveen et 
al., 2007). It was also found that mutations in SDHC, SDHB and SDHD are correlated 
with the rare development of a combination of hPGL and GIST (gastrointestinal stromal 
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tumor), defined as Carney-Stratakis syndrome, and with the non-familial Carney triad, 
characterized by the presence of extra-adrenal paragangliomas, GIST and pulmonary 
chondromas (Stratakis and Carney, 2009). 
Loss-of-function germline mutations in another TCA nuclear-encoded enzyme, 
fumarate hydratase (FH), which catalyzes the reversible conversion of fumarate to 
malate, predispose to hereditary leiomyomatosis and renal cell cancer (HLRCC), 
inherited leiomyomas (generally benign tumors of the smooth muscle), and renal (type 
II papillary and collecting duct) carcinoma (Launonen et al., 2001; Tomlinson et al., 
2002). There is evidence suggesting that FH mutations may also be involved in the 
pathogenesis of breast, bladder, and testicular (Leydig cell) cancers (Carvajal-Carmona 
et al., 2006; Lehtonen et al., 2006). Similar to SDH in hPGL, enzymatic activity of FH 
is absent in HLRCC tumors and loss of the wild-type allele is observed in the majority 
of tumors (Tomlinson et al., 2002).  
Somatic mutations in isocitrate dehydrogenase (IDH), which catalyzes the oxidative 
decarboxylation of isocitrate to α-ketoglutarate in TCA cycle, have been identified in 
gliomas and acute myelogenous leukemia (AML)( Carroll et al., 2010; Parsons et al., 
2008; Bleeker et al., 2009; Yan et al, 2009). While FH and SDH mutations are typically 
loss-of-function, and for this reason their genes believed tumor suppressors, some IDH 
mutations lead to a gain of a new NADPH-dependent α-ketoglutarate-reductase activity 
with production of a less known metabolite, 2-hydroxyglutarate (2HG), significantly 
accumulated in glioma cells and blood of AML patients and defined “oncometabolite”, 
to portray its potential oncogenic contribution (Dang et al., 2009; Frezza et al., 2010). 
In all these three genetic-metabolic events, the underlying mechanism of tumorigenesis 
involves the accumulation of metabolites that convey oncogenic signal. Even though the 
role of 2HG is still unclear, succinate and fumarate accumulation, observed in the 
tumors with mutations in SDH and FH respectively, has been linked to the tumoral 
progression by hypoxia inducible factor (HIF) activation. HIF is known to orchestrate 
the metabolic and genetic reprogramming required to sustain tumor cell growth, 
vascularization and proliferation. The molecular link between TCA dysfunction and 
HIF activation was initially proposed by Selak and co-workers (Selak et al. 2005), but 
subsequently followed and proved by several other research groups (Gottlieb and  
Tomlinson, 2005; Isaacs et al., 2005; Pollard et al., 2005; Hewitson et al., 2007; Porcelli 
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et al., 2010). In summary, in normoxic condition, HIF1α prolyl 4-hydroxylase, master 
regulator of HIF stability, hydroxylates two proline residues on the oxygen-dependent 
degradation domain of HIF1α, targeting it to the ubiquitin-proteasome degradation 
machinery. This hydroxylation requires oxygen and α-ketoglutarate and produce carbon 
dioxide and succinate. For this reason, the succinate accumulation in SDH-deficient cell 
tumors impairs PHDs activity and leads to HIF1α stabilization also under normoxic 
conditions, a phenomenon that has been defined as pseudohypoxia (Gottlieb and 
Tomlinson, 2005). Also fumarate has been demonstrated to be a potent inhibitor of 
PDHs (Isaacs et al., 2005). Furthermore, other biochemical studies showed that PHD 
activity is competitively inhibited by succinate or fumarate and, therefore, the ratio 
between α-ketoglutarate and succinate (or fumarate) rather than the absolute  
concentrations of these metabolites dictates PHD activity (MacKenzie et al., 2007; 
Porcelli et al., 2010). However, the activity of other enzymes could be affected by the 
TCA cycle intermediates accumulation like the α-ketoglutarate-dependent dioxygenases 
(Schofield and Ratcliffe, 2004) or the histone demethylase JMJD3 (Cervera et al., 
2009), carrying to speculate about the mitochondria to-cytosol and mitochondria to-
nucleus signalings of succinate and fumarate, with the power to regulate gene 
expression.  
In addition, somatic and germinal mutations in NDUFA13, subunit of respiratory 
complex I, are linked to Hürthle cell tumors of the thyroid (Maximo et al., 2008), and  
its down-regulation or loss of its expression has been reported in renal cell carcinomas 
(RCC) and colorectal carcinoma  (Maximo et al., 2008; Gong  et al., 2007; Kalakonda et 
al., 2007).  
Then, mutations in gene of the polymerase-gamma (POLG) gene, the only DNA 
polymerase known to function in human mitochondria, was mutated in 63% of breast 
tumors (Singh et al., 2009a; Chan and Copeland, 2009; Wong et al., 2008) inducing a 
depletion of mtDNA, decreased mitochondrial activity, decreased mitochondrial 
membrane potential, increased levels of reactive oxygen species and increased matrigel 
invasion (Singh et al. 2009a,b).  
Altogether, these findings suggest a role for OXPHOS dysfunction in cancers and in 
promoting tumorigenicity.  
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Mitochondrial genes involved in defective OXPHOS in cancer 
Mitochondrial DNA mutations have been increasingly identified in various types of 
cancer (Polyak et al., 1998; Fliss et al., 2000). A number of mtDNA rearrangements and 
amplifications have been reported in acute myeloid leukemia (Boultwood et al., 1996) 
and point mutations in human colorectal cancer cells (Polyak et al., 1998), esophageal, 
ovarian, thyroid, head, neck, lung, bladder, renal, and breast cancer cells (Fliss et al., 
2000; Brandon et al., 2006; Chatterjee et al., 2006; Shidara et al., 2005).  
Mutations in mtDNA have been described in tRNAs, rRNA, protein encoding regions, 
and important feature, in D-loop region, the single control region of mtDNA for 
replication and transcription of its OXPHOS genes. Mutations in the D-loop region 
result in altered binding affinities of the nuclear proteins involved in mtDNA replication 
and transcription leading to the depletion of mtDNA content (Clayton, 2000). Decreased 
mtDNA level has been reported in breast (Tseng et al., 2006), renal (Selvanayagam and 
Rajaraman, 1996), hepatocellular (Lee et al., 2005; Yin et al., 2004), gastric (Wu et al., 
2005), liver (Yin et al., 2004), and prostate tumors (Moro et al., 2008). Depletion of 
mtDNA is also supported by a decrease in OXPHOS levels in renal tumors (Simonnet et 
al., 2002). Therefore, it has been demonstrated that reduced mtDNA leads to increased 
invasiveness and aggressive disease (Simonnet et al., 2002; Mambo et al., 2005).  
Since the mitochondrial mutations affect the synthesis of peptides that are important 
components of various respiratory chain complexes, the ultimate outcome is likely to be 
defective OXPHOS. MtDNA-derived subunits of respiratory chain complex I (7/45 
subunits: NADH dehydrogenase subunits ND1 to ND6 and ND4L), III (1/11subunits: 
cytochrome b) and IV (3/13 subunits, cytochrome c oxidase subunits COXI to III) have 
been found altered in various types of cancers (Brandon et al., 2006; Lu et al., 2009) 
(Fig. 6). 
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Figure 6. The four complexes of the respiratory chain are schematized and the various mutations found 
in cancer cells that impact complex subunits and assembly factors are highlighted: ND1-6 and ND4L 
(nicotinamide adenine dinucleotide, NADH, dehydrogenase subunits 1–6 and 4L); SDHA–D (succinate 
dehydrogenase subunits A–D), SDHAF2 (SDH assembly factor 2); cytochrome b; COXI–III (cytochrome 
c oxidase subunits I–III). From Lemarie and Grimm, 2011. 
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An important question was if these mutations act as a significant cause of 
tumourigenesis or if they merely constitute a side effect of tumour development. Only 
recently different groups have supported the likelihood of a causative effect on tumour 
progression.  In  thyroid  cancer  cell  lines  (Abu-Amero  et  al., 2005), renal (Gasparre 
et al., 2008) and thyroid oncocytomas (Gasparre et al., 2007) for example, mtDNA 
mutations in the complex I subunits ND1, ND2 and ND4–6 were shown to be 
associated with complex I deficiency and enhanced proliferation. Therefore, human 
cells bearing a ND5 mutation were associated with a drop in oxygen consumption, 
increased ROS production, potentiated glucose dependency and enhanced tumour 
growth (Park et al., 2009). MtDNA mutations of the complex IV subunit COXI were 
found in 11 to 12% of all prostate cancer patients screened in one study and associated 
with a complete loss of the COXI protein in tumoral tissues and an increased tumour 
growth rate (Petros et al., 2005). It was shown that mutations in mtDNA of complex I 
(ND1) and III (cytochrome b) led to a considerable decrease of both enzymatic 
activities and to ROS overproduction in thyroid carcinoma (Bonora et al., 2006). In 
accordance, another study established that the ND6 mutation confers a high metastatic 
potential to its transmitochondrial cybrid and was associated with a profound complex I 
deficiency and an overproduction of ROS (Ishikawa et al., 2008). The 
transmitochondrial cybrid cell model, in which mitochondria from tumour cells are 
transferred into cells devoid of their own mtDNA, allows to study mitochondrial 
mutations independently of their nuclear DNA. Another result obtained through a 
cybrid model for the relevance of mtDNA mutations in cancer progression, was 
provided by a mutant form of ATP6 (one of the two mtDNA-coded subunits of ATP 
synthase), that showed the positive contribution of the  ATP6 mutant to tumour growth 
in mice through a decreased respiration rate, a higher proliferation in culture and a 
significant resistance to apoptosis (Shidara et al., 2005). 
To summarize, it seems that mitochondrial mutations are linked to the tumoral progress 
by determining several effects, like (i) the decrease of one or more respiratory chain 
complex activities, (ii) an impaired electron flux along the respiratory chain associated 
with a reduced oxygen  consumption, (iii) an increase in the electron leakage outside the 
affected respiratory chain leading to an increase of the basal ROS production and  to the 
subsequent alterations of mtDNA, (iv) a global resistance to apoptotic processes 
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(Kwong et al., 2007) and  finally (v) an enhanced proliferation and growth, instigating 
the development of tumour formation (Lu et al., 2009). 
To conclude, it appears clear that, among the complex activities affected by both 
nuclear and even more mitochondrial mutations, complex I activity certainly holds a 
central position, having its subunits genes the highest mutational rate of mtDNA (Fig. 
7): in particular, ND1 gene is indeed a hotspot for somatic changes with a ratio of over 
3, meaning that mutations occur in this gene at a frequency more than three times higher 
than expected on the basis of the gene length. Our research group showed and explained 
the involvement and effects of a MTND1 truncating mutation in vivo in oncocytic 
tumors and also in the only existing cell model of thyroid oncocytoma, demonstrating as 
the strong energetic impairment observed to be associated to this mutation was due to 
the complex I disassembly (Gasparre et al., 2007, 2008, 2010, 2011). 
 
 
 
  
 
 
                              
 
 
 
 
 
      
 
 
  
 
  
                          
Figure 7. Frequency ratio of mtDNA mutations occurring in protein
changes. (B) Potentially pathogenic changes as predicted by PolyPhen. Different shades of
different susceptibility to mutations occurrence. Scale value from 0 to above
mutation frequencies (obtained dividing the single values
overall number of mutations) over the percentage
below 0.7 have been arbitrarily de
with values above 1.5 have been de
Acta.2011.              
 
-coding genes. (A) Somatic
 3 was calculated as ratio of 
 reported in Tab.1A and B per gene by the 
 of mtDNA occupied by the gene. Genes with values 
fined as “preserved from the occurrence of mutations”, whereas genes 
fined as “mutational hotspots”. From Gasparre et al., 
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COMPLEX I : STRUCTURE, ASSEMBLY AND FUNCTION 
 
Complex I, NADH:ubiquinone oxidoreductase, is the largest membrane protein 
assembly known and has a central role in energy production by the mitochondrial 
respiratory chain, providing about 40% of the proton-motive force required for the 
synthesis of ATP. Eukaryotic complex I is located in the mitochondrial inner membrane 
and protrudes into the matrix to form an L-shaped structure (Fig. 8). This structure 
consists of a hydrophilic peripheral arm with a hydrophobic membrane arm lying 
perpendicular to it (Friedrich and Bottcher, 2004). The L-shaped structure is conserved 
from NDH-1 in Escherichia coli, which is a homolog of eukaryotic complex I 
(Guenebaut V, et al., 1998; Sazanov LA et al., 2003), to bovine heart complex I 
(Friedrich and Bottcher, 2004). Over the years, extensive analyses of the intact complex 
and various subcomplexes from bovine heart mitochondria have played an important 
role in defining its subunit composition, especially by Walker and colleagues. In fact, 
they have resolved the intact complex I, with mildly chaotropic detergents, into four 
subcomplexes, Iα, Iβ, Iγ and Iλ (Carroll et al., 2002, 2003; Sazanov et al 2000). Their 
separation has been carried out by three independent methods (1D SDS-PAGE, 2D 
IEF/SDS-PAGE, and reversed-phase HPLC) and subsequent analysis of the individual 
subunits has been done by mass fingerprinting and mass spectrometry (Carroll et al., 
2003). Subcomplex Iα consisted of the hydrophilic peripheral arm plus part of the 
hydrophobic membrane arm, as subcomplex Iβ contained the main part of the 
membrane arm. However, some subunits have not been found in either Iα or Iβ and 
have been together considered as subcomplex Iγ; under slightly different conditions, Iα 
dissociated to produce subcomplex Iλ representing the hydrophilic or peripheral arm. 
The further crystal structure defining of the hydrophilic domain of complex I in the 
bacterium Thermus thermophilus has allowed to make clear the relative positions of the 
8 subunits that compose the peripheral arm of complex I (Sazanov et al., 2006). It 
consists of 2 functional modules, an electron input module (N module) and an electron 
output module (Q module), and comprises all redox active cofactors (Fig. 9). The N 
module contains an NADH oxidation site with an FMN molecule as the primary 
electron acceptor, while the Q module contains a ubiquinone reduction site. Electrons 
from the oxidation of NADH are transferred via FMN and a series of Fe–S clusters to 
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ubiquinone. The membrane arm or the proton translocation module (P module) contains 
the 3 subunits, ND2, ND4 and ND5. They are highly hydrophobic proteins, containing 
around 15 transmembrane stretches, and are antiporter-like subunits presumably 
involved in proton-pumping activity (Mathiesen et al., 2002). However, how electron 
transfer is coupled to proton translocation, either by direct association through protein 
binding sites or indirectly through conformational changes of the enzyme, remained 
obscure because of the lack of a high quality 3-dimensional structure of complex I 
(Belevich et al., 2006; Faxen et al., 2005). 
 
 
                   
 
 
 
 
 
 
             
 
Figure 8. Subunit composition of mammalian complex I. Subunits have been grouped by the 
subcomplex they have been identified in, after complex I fractionation according to Walker and co-
workers (Carroll et al., 2003). The human subunit  nomenclature is shown in dark blue, the bovine one in 
light blue. Subunits depicted with a * have been reported harbouring pathogenic mutations causing 
complex I deficiency. From Janssen et al., 2006. 
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Figure 9. Schematic graph of functional structure of mammalian mitochondrial complex I. The matrix 
arm and the membrane arm form an L-shaped structure, with an angle of 100°. It is composed of three 
conserved functional modules: the NADH dehydrogenase module (N module), the electron transfer 
module (Q module) and the proton translocation module (P module). The positions of 14 core subunits 
are indicated, all of which are highly conserved from prokaryotes to eukaryotes. From Mimaki M et al., 
2011. 
 
 
 
 
 
 
More recently, the X-ray structures of the membrane domain of complex I from E.coli 
at a resolution of 3.9 Å and of the entire complex I from T. thermophilus at a resolution 
of 4.5 Å were solved (Efremov et al.,2010). These findings defined the positions of all 
of the subunits and revealed the long horizontal α-helical structure of the membrane 
domain of complex I, suggesting that the conformational changes at the interface of the 
matrix and membrane domains may drive the long amphipathic α-helices in a piston-
like motion, thereby leading to proton translocation. In addition, the low resolution X-
ray structure of mitochondrial complex I from the aerobic yeast Yarrowia lipolytica was 
also reported (Hunte et al., 2010). The arrangement of functional modules suggested the 
conformational coupling of redox chemistry with proton pumping. A long helical 
element in the NuoL/ND5 subunit stretches across the matrix face of the membrane 
domain of complex I and is suggested to be critical for transducing conformational 
energy to proton-pumping elements in the distal module of the membrane arm. 
Bovine and human mitochondrial complex I consist of 45 different subunits, nuclear- 
and mitochondrial-DNA coded, with a total molecular weight of ~980 kDa (Carroll et 
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al., 2003, 2006). Generally, the NDU prefix (from NADH dehydrogenase ubiquinone) 
is used to distinguish the nuclear-encoded subunits from those mitochondrial-encoded 
ones, for which the ND prefix (from NADH dehydrogenase) is used. Seven subunits, 
ND1–ND6 and ND4L, are encoded by mitochondrial DNA, and are homologs of the 7 
membrane subunits in bacterial NDH-1, forming the major part of the membrane 
domain (Janssen and al. 2006; Hirst et al. 2003). The mtDNA-encoded subunits are 
thought to be involved in proton translocation and ubiquinone binding (P module, Fig. 
9), as their bacterial homologs have these functions (Janssen and al. 2006; Friedrich and 
Bottcher, 2004). The remaining 38 subunits are encoded by nuclear DNA and imported 
into the mitochondria (Hirst et al. 2003; Stojanovski et al., 2003; Hoogenraad et al., 
2002). Seven of the nDNA-encoded subunits, NDUFV1, NDUFV2, NDUFS1, 
NDUFS2, NDUFS3,  NDUFS7 and NDUFS8, represent the “core subunits” in the 
peripheral arm of complex I, catalyzing the oxidation of NADH and electron transfer 
(Janssen and al. 2006; Lazarou et al. 2009). The N module, responsible for the oxidation 
of NADH, includes at a minimum the NDUFV1, NDUFV2 and NDUFS1 subunits. The 
Q module, responsible for the electron transfer to ubiquinone, includes at a minimum 
the NDUFS2, NDUFS3, NDUFS7 and NDUFS8 subunits (Vogel et al., 2007) (Fig. 9). 
The remaining 31 nDNA-encoded subunits are referred to as “supernumerary” subunits 
because they have no counterparts in NDH-1(Carroll et al., 2006). Most of the 
supernumerary subunits are not involved in enzymatic activity, and their actual function 
is still unknown. It has been proposed that the eukaryotic supernumerary subunits assist 
in the biogenesis of the complex and support its structural stability (Carroll et l., 2003, 
Friedrich and Bottcher, 2004).   
The assembly of a so large protein complex was demonstrated to be a very complicated 
process, especially due to its dual genomic controls and to the numerous subunits. The 
nDNA-encoded subunits must assemble in coordination with the hydrophobic mtDNA-
encoded subunits to form the properly functioning mature complex; however, the 
assembly pathway is still not completely understood. A number of model systems have 
been employed to study the assembly of the eukaryotic complex, in various organisms 
such as the green alga Chlamydomonas reinhardtii, the fungus Neurospora crassa, the 
nematode Caenorhabditis elegans, and cultured mammalian cell lines. In particular, 
assembly studies in rodent and human ND-subunit mutant cell lines have demonstrated 
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that subassemblies of nDNA-encoded subunits could be formed in the absence of 
mtDNA-encoded subunits (Bourges et al. 2004; Potluri et al., 2004). Cells lacking 
mtDNA, which lose all of the mtDNA-encoded subunits, maintain the levels of some 
nDNA-encoded subunits of the peripheral subcomplex that consists of, at least, 
NDUFS2, NDUFS3 and NDUFS8 (Bourges et al. 2004). Therefore, it has been 
suggested that the presence of the mtDNA-encoded subunits is not required for the 
formation of the peripheral arm subcomplex (Potluri et al., 2004). However, the entry 
points of the mtDNA-encoded subunits in the assembly process and their roles in the 
stability of the complex had remained elusive. Recent research using several mouse cell 
lines deficient for ND4, ND6, and a combination of ND6 and ND5 proposed five entry 
points of the mtDNA-encoded subunits in the complex I assembly process (Perales-
Clemente et al., 2010). This study defined a first entry point for ND1 in the ~400 kDa-
subcomplex and a second entry point for ND2, ND3 and ND4L in the ~460 kDa-
subcomplex. Subsequently, ND4, ND6 and ND5 appear to be incorporated into 
complex in order at a third, fourth and fifth entry point, respectively. Others interesting 
studies on Chinese hamster cells clarified the function of some subunits in the assembly 
process (Scheffler et al., 2004), as that of NDUFA1 (Yadava et al., 2002). The insertion 
and stabilization of NDUFA1 in the mitochondrial inner membrane were shown to 
require mtDNA-encoded subunits, in particular, ND4 and ND6 (Yadava et al., 2004). 
NDUFA1 is also unstable in the absence of other membrane domain subunits like 
NDUFB11 (Scheffler et al., 2004). Chinese hamster fibroblasts also revealed that the 
stability of the peripheral arm subunits NDUFS1, 2, 3, 7, 8 and NDUFV1 and NDUFV2 
were unaffected by the absence of  NDUFA1, although holo-complex I was not 
assembled (Scheffler et al., 2004). These data suggest that the peripheral arm can be 
assembled in the absence of the membrane arm, similar to its assembly in N. crassa 
(Tuschen et al., 1990). NDUFA1 was also suggested to form an assembly intermediate 
consisting of mtDNA- and nDNA-encoded subunits and to serve as a membrane anchor 
to which membrane subunits are attached during complex I assembly (Yadava et al., 
2004). Furthermore, recent bioinformatic analyses of the co-evolution of complex I 
subunits coupled with yeast two-hybrid studies revealed the interaction of human 
NDUFA1 with ND1 and ND4, and the interaction of human NDUFC2 with ND4 
(Gershoni et al., 2010). The findings reinforce the important role of NDUFA1 in 
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forming an assembly intermediate composed of mtDNA-and nDNA-encoded subunits. 
The direct physical interaction between NDUFC2 and ND4 indicates that these subunits 
may be incorporated into the membrane arm together. Since ND1, ND4 and NDUFA1 
are essential for the assembly of the membrane arm of complex I, NDUFC2 may be also 
important for the assembly process. Other supernumerary subunits have also been 
proposed to assist in complex I biogenesis and support its structural stability, as 
NDUFS5, NDUFB7 and NDUFA8 (Szklarczyk et al., 2011). Besides, the assembly 
process of a such large number of subunit into the mature holo-complex I involves a 
number of assembly factors. These assembly factors are not part of the final structure of 
the holo-enzyme, but they are involved in biogenesis process and are found in some 
complex I intermediates, indicating their functions in complex I assembly/stability.  
To summarize research findings about the biogenesis of complex I in mammals, 
Mimaki and colleagues recently (2011) proposed the assembly model illustrated in 
figure 10. In the early assembly stage, the core subunits NDUFS2 and NDUFS3 form a 
small hydrophilic assembly complex, which further expands by the incorporation of the 
other hydrophilic subunits, like NDUFS7, NDUFS8, and later, possibly NDUFA9. This 
peripheral complex is anchored to the membrane by the assembly factors Ndufaf3 and 
Ndufaf4 (Saada et al., 2009). The complex combines with a small membrane complex 
containing the mtDNA-encoded ND1 subunit, for which C20orf7 is involved in 
assembly or stability (Sugiana et al., 2008), to form a ~400-kDa assembly intermediate 
(Lazarou et al.,2007). This ~400-kDa complex incorporates with a ~460-kDa membrane 
complex containing ND3, ND6, ND2, ND4L and NDUFB6 to form a ~650-kDa 
complex under the  presence  of the assembly factors of Ndufaf1, Ecsit and ACAD9 
(Sugiana et al., 2008). With the association of another membrane complex containing 
ND4, ND5 and possibly NDUFC2, an ~830 kDa assembly intermediate is formed 
(Gershoni et al., 2010). The assembly  factor Ndufaf2 is associated with this ~830 kDa-
complex and would be required in the late stage of CI assembly (Hoefs et al., 2009). 
Meanwhile, a hydrophilic complex, the NADH: dehydrogenase module, is built with 
some nDNA-encoded subunits that are directly or indirectly involved in binding and 
oxidizing NADH. With the addition of the NADH:dehydrogenase module and the 
remaining subunits, the mature holo-complex I is assembled. In this complicated and 
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elaborate assembly process, more assembly factors with unknown functions including 
Ind1, MidA, FOXRED1 and undiscovered proteins are involved. 
 
 
 
 
 
 
 
 
Figure 10. The assembly model of human complex I biogenesis. The initial core subunits NDUFS2 and 
NDUFS3 form a small hydrophilic assembly complex, which further expands by the incorporation of 
hydrophilic subunits such as NDUFS7, NDUFS8 and later NDUFA9. This peripheral complex, together 
with a small membrane complex containing mtDNA-encoded subunit ND1, forms a ~400 kDa assembly 
2intermediate. This ~400 kDa complex incorporates with a ~460 kDa membrane complex containing 
ND3, ND6, ND2, ND4L and NDUFB6 to form a ~650 kDa complex. With the association of another 
membrane complex having ND4, ND5 and probably NDUFC2, an ~830 kDa assembly intermediate is 
formed. Meanwhile, a hydrophilic complex, NADH: dehydrogenase module (N module) is assembled by 
some nDNA-encoded subunits directly or indirectly involved in binding and oxidizing NADH. With the 
addition of the N module and remaining subunits (such as the intermembrane space subunits NDUFA8 
and NDUFS5), mature complex I is assembled. The core subunits are colored with red, the rest of nDNA-
encoded subunits are colored with blue. The mtDNA-encoded-subunits are in green. From Mimaki et al., 
2011. 
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Mitochondrial diseases encompass a large assemblage of clinical disorders, commonly 
involving tissues with high energy requirements, such retina, brain, heart, muscle liver 
and endocrine system. Moreover mitochondrial dysfunctions also contribute directly or 
indirectly to the aging process and tumor formation. Approximately 300 mtDNA 
alterations have been identified as the genetic cause of mitochondrial diseases and one-
third of these alterations are located in the coding genes for OXPHOS proteins. 
Although the understanding of the pathogenesis of mitochondrial disorders has 
improved considerably in last decade, the most disappointing area is the lack of efficient 
treatments for the patients. Indeed, they are still treated with vitamins and cofactors 
mixture, which are harmless but largely inadequate and inefficient (DiMauro and 
Mancuso, 2007).   
In last years a gene therapy was proposed and tried in vitro as a potential therapeutic 
option, namely allotopic expression. The term indicates the nuclear expression of the 
corrected wild-type mtDNA subunit engineered for mitochondrial import, which once 
transferred within mitochondria may compete with the native mutant mtDNA subunit to 
complement the biochemical defect (Gray et al., 1996). This strategy has been applied, 
for example, to the LHON and NARP mutations:  in vitro studies have in fact reported 
the successful complementation of the OXPHOS phenotype in transmitochondrial 
cytoplasm hybrid (cybrid) cell lines (Manfredi et al., 2002; Guy et al., 2002), but 
subsequent studies compromised these results (Oca-Cossio J et al., 2003; Perales-
Clemente E et al., 2011), due to the lack of convincing evidence showing that the 
mitochondrial defect complementation was really achieved by allotopic expression. 
Perales-Clemente and co-workers demonstrated in fact how an apparent functional 
complementation can also depend on selection of revertant mtDNA genomes. Our 
research group has previously characterized cybrid cell models harboring the 
homoplasmic disruptive m.3571insC MTND1 mutation typical of oncocytic tumors, 
showing that it provokes complex I disassembly in vitro (Bonora et al., 2006), and in 
vivo (Porcelli et al., 2010). We also demonstrated that complex I disassembly induced 
an increased α-ketoglutarate/succinate ratio, due to inhibition of NADH oxidation to  
NAD+, which ultimately leads to chronic HIF1α  degradation (pseudonormoxia) and to 
a reduced tumorigenic potential in two different types of cancer, such as osteosarcoma 
and thyroid carcinoma. The m.3571insC MTND1 mutation exhibits a threshold effect on 
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tumor development, because reduction of tumorigenesis is displayed only when the 
mutation load is above a well defined value. These findings allowed us to define 
MTND1 gene as a novel type of tumor-implicated gene, named by us the double-edged 
oncojanus (Gasparre et al., 2011). Indeed, when m.3571insC MTND1 mutation load is 
below the threshold, we demonstrate that complex I is assembled, HIF1α is stabilized 
and in vivo tumor growth of osteosarcoma and thyroid carcinoma is increased. We show 
in this way the pivotal role of complex I during tumor onset in at least two tumor 
models. 
We believe that the rescue of complex I assembly and function in our homoplasmic 
cybrid model, by allotopic expression of the wild type ND1 protein, can be considered 
indisputable. That because m.3571insC MTND1 mutation causes the translation of a 
truncated ND1 subunit, then degraded, and for this reason unable to compete with the 
nuclear-coded one, so avoiding ambiguous results. Besides, we took advantage by a 
previously optimized combination of methods for the detection of low levels of 
m.3571insC MTND1, to ascertain the mutation reversion, thus allowing us 
to discriminate false positives allotopic clones from revertants. Achieving this goal 
would allow us to obtain two important results, namely to make finally feasible and 
reproducible the allotopic expression technique and also to further confirm our previous 
results on complex I implication in tumorigenesis process.  
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                     Materials and methods 
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Cell cultures and growth conditions 
Cybrids OS-93 bearing the m.3571insC in MTND1 gene (93% of mutation load) were 
generated from human osteosarcoma 143B.TK cells and previously characterized 
(Porcelli et al., 2010). OS-93ND1 cell clone was obtained after stable transfection of OS-
93 with recoded ND1 construct. A previously characterized (Porcelli et al., 2010) 
parental control cybrid (CC), homoplasmic wild-type for the m.3571insC, was also 
used. OSC-93 and OSC-93ND1 were derived from xenografts after in vivo injection of 
OS-93 and OS-93ND1 cells, respectively. All cell lines were grown in Dulbecco's 
modified Eagle's medium (DMEM) with 10% FBS, 2 mmol/L L-glutamine, 100 
units/mL penicillin, 100 µg/mL streptomycin, 0.1 mg/mL bromodeoxyuridine, and 50 
µg/mL uridine. Cultures were grown in a humidified incubator at 37° C with 5% CO2.  
All cell lines were authenticated by mtDNA genotyping. Occurrence of the m.3571insC 
mutation and accurate quantification of heteroplasmy levels as previously described 
(Kurelac et al., 2010) were verified before and after explant as well as before each in 
vitro experiment. 
 
ND1 construct and clone stable generation 
Human mitochondrial MTND1 gene was nucleus-recoded and engineered in p3XFLAG-
CMV-14 vector in the Laboratorio di Genetica Medica (Sant’Orsola Hospital, Bologna). 
Recoded ND1 construct was transfected in OS-93 cell line and transfection was carried 
out with Lipofectamine2000 (Invitrogen, Milan, Italy) following manufacturer’s 
instructions. 
After 24h, cells were incubated in a medium containing the 500ug/ml G418 antibiotic 
and ten cell clones were isolated. These clones were incubated  in glucose-free DMEM 
supplemented with 5 mmol/L galactose, 5 mmol/L Na-pyruvate, and 10% FBS 
(DMEM-galactose) for 24h, in order to select only those cells able to use oxidative 
phosphorylation through the restore of complex I assembly and function. Under this 
condition, two cell clones were isolated, namely OS-93ND1-B and  OS-93ND1-C. 
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Cell viability measurements 
Cells (3x104) were seeded into 24-well plates and, after 24 hours, incubated in DMEM-
galactose. Cell viability was determined by the colorimetric sulforodhamine B (SRB) 
assay, following the manufacturer’s conditions. Briefly, at the end of incubation time, 
cells were fixed with 50% trichloroacetic acid (TCA) for 1 hour at 4°C, washed 5 times 
with H2O and finally dried for 1 hour at room temperature. Cells were then stained with 
SRB 0.4% diluted in 1% acetic acid for 30 min at room temperature, washed 4 times 
with 1% acetic acid, and disrupted with 10 mM Tris-HCl pH 9.8. The absorbance of 
SRB was detected with Victor3 plate reader (Perkin Elmer) at the wavelength of 560 
nm. 
 
SDS-PAGE and Western blotting 
Digitonin-isolated mitocondria were prepared from 5 x 106 cells and resuspended in 
PBS containing 2% DDM. After 15 min of incubation in ice, the sample was 
centrifuged for 30 min at 13 000 g (4°C) and the supernatant was mixed with an equal 
volume of tricine sample buffer containing 2% (v/v) 2-mercaptoethanol. The mixture 
was kept at room temperature for 60 min. Protein (50 µg protein/lane) was separated on 
10% polyacrylamide gel and transferred on nitrocellulose membrane (Bio-Rad) that 
were subsequently incubated with primary antibody against ND1 (1:1000, a gift from A. 
Lombes, Unite de Recherche INSERM 153, Hospital de la Salpetriere, Paris, France), 
NDUFV1 (1:1000, Sigma-Aldrich) and VDAC (1:1000, BioVision, Mountain View, 
CA, USA). Peroxidase-conjugated anti-rabbit IgGs  secondary antibodies were used 
(1:2000, Jackson Immunoreaserch). Chemiluminescence signals were measured with a 
Kodak molecular imaging apparatus (Kodak, Rochester, NY, USA). 
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2D Blue Native-SDS PAGE and western blotting  
Strips from the first dimension Blue Native electrophoresis were used for 2D-SDS 
electrophoresis as reported in (Calvaruso et al. Methods 2008). Western blotting 
analysis was performed as above. 
 
Clear Native Electrophoresis (CNE) and in gel activity assay 
Digitonin-isolated mitochondria were solubilized using 0.4% (w/v) n-dodecyl-β-D-
maltoside (DDM) and 100ug of proteins were separated on 5-13% gradient 
polyacrylamide gel (Wittig et al., 2006). Complex I IGA was determined by incubating 
the gel with 2 mM Tris-Cl (pH 7.4), 0.15 mM NADH, and 2.5 mg/ml MTT at room 
temperature for 1 h. The reaction was stopped with 50% methanol and 10% acetic acid, 
and the gel was analyzed with a Kodak molecular imaging apparatus (Kodak, 
Rochester, NY, USA). 
 
ATP synthesis measurement 
The measurements of mitochondrial ATP synthesis were done in cells grown in 
DMEM-glucose according to Manfredi et al. 2002b, with minor modifications. Briefly, 
after trypsinization, cells were resuspended (7x106/mL) in buffer A [10 mM KCl, 25 
mM Tris-HCl, 2 mM EDTA, 0.1% bovine serum albumin, 10 mM potassium phosphate, 
0.1 mM MgCl2 (pH 7.4)], kept for 15 minutes at room temperature, and then incubated 
with 50 µg/mL digitonin for 1 min. After centrifugation, the cells pellet was 
resuspended in buffer A and aliquots were taken to measure ATP synthesis, protein 
content, and citrate synthase activity. Aliquots of cells were incubated with 5 mM 
malate plus 5 mM pyruvate (complex I-driven substrates) in the presence or absence of 
10 µg/mL oligomycin, or with 10 mM succinate plus 2 µg/mL rotenone (complex II-
driven substrate). The reaction was started by addition of 0.2 mM ADP in the presence 
of luciferine/luciferase, as detailed by the Sigma Aldrich kit manufacturer’s  
instructions, and chemiluminescence was determined as a function of time with a 
luminometer. After addition of 10 mM oligomycin, the chemiluminescence signal was 
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calibrated with an internal ATP standard. The rate of ATP synthesis was expressed as a 
ratio of citrate synthase activity (Trounce et al., 1996). Protein concentration was 
determined according to Bradford (Bradford, 1996). 
 
In vivo studies 
Cells (3x106) were suspended in 0.2ml sterile PBS and injected subcutaneously in 
immunodeficient 4-7 week-old athymic Crl:CD-1-Foxn1nu/nu mouse strain (referred to 
as nude mice, purchased from Charles River, Italy). Experiments were authorized by the 
Institutional Review Board of the University of Bologna and performed according to 
Italian and European guidelines. Individually tagged virgin female mice (5-15 per 
experimental group) were used. Tumor growth was assessed with a caliper; volume was 
calculated as pi[√(a*b)]3/6, where a=maximal tumor diameter, and b=tumor diameter 
perpendicular to a. Lungs were stained with black India ink and fixed in Fekete's 
solution to better outline metastases, which were then counted using a dissecting 
microscope.  
 
Immunohistochemistry 
Immunohistochemical staining (IHC) was performed on paraffinized xenograft sections, 
which were dewaxed, rehydrated, and retrieved using a Tris-EDTA pH 9.0 solution (20 
min at 98°C). Endogenous peroxidise activity was quenched with a methanol/H2O2 
1,5% solution. 
Primary antibodies against MTND6 complex I subunit (Invitrogen, Milan, Italy) and 
HIF1α (Upstate Biotech, Billerica, MA, USA) were incubated overnight and processed 
with a non-biotin-amplified sytem (NovoLink, Milan, Italy) according to the 
manifacturer’s instructions. The reaction was developed with 3-3’-diaminobenzidine 
tetrahydrochloride/H2O2 solution.Sections were counterstained with hematoxlin, 
dehydrated and mounted in Bio-Mount (Bio-Optica, Milan, Italy).  
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ΤCA metabolites extraction and measurement 
Metabolites α-KG and SA were extracted from tumors (35mg) in cold methanol 
/chloroform/water in a ratio of 2:1:0.7 in presence of  13C4  succinic acid as internal 
standard.  Sample was maintained on ice for 5min, vortexed twice and centrifuged for 
5min at 3000rpm at 4°C. To the upper phase, chloroform/water in a ratio 1:1 was added 
and sample was vortexed and centrifuged for 5min at 3000rpm at 4°C. The upper phase 
was separated from the lower organic phase and lyophilized. Samples were then 
analyzed by mass spectrometry. 
 
Electron microscopy (EM)  
Xenograft biopsies were immediately collected and processed, as previously reported 
(Ambrosini-Spaltro et al., 2006). Sections (1µm) were stained with 1% toluidine blue 
for morphology control and EM area selection. Thin sections were observed with JEM-
1011 Transmission Electron Microscope (Jeol, Ltd). For each xenograft at least two 
different areas were analyzed to rule out intratumor heterogeneity.  
 
Pimonidazole staining 
Animals were injected intraperitoneally with 60mg/kg pimonidazole (Hypoxyprobe-1 
Plus Kit, HPI, Burlington, MA) 3h prior to sacrifice. Xenografts were snap-frozen and 
cut in 10µm slices. Tissues were fixed for 20min with cold acetone, kept for 1h with 
PBS containing 5% FBS and incubated for 1h with FITC-MAb1 antibody (1:10). 
Fluorescence was visualized with a digital imaging system using an inverted 
epifluorescence microscope with 63X/1.4 oil objective (Nikon Eclipse Ti-U, Nikon, 
Japan) at 488nm. Images were captured with a back-illuminated Photometrics Cascade 
CCD camera system (Roper Scientific, Tucson, AZ, USA) and elaborated with 
Metamorph acquisition/analysis software (Universal Imaging Corp., Downingtown, PA, 
USA). 
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Fluorescent PCR 
Fluorescent PCR reaction was performed using AmpliTaq Gold polymerase (Applied 
Biosystems, Foster City, CA, USA) with a fluorescently labelled forward primer 
(Kurelac et al, 2011). PCR products were loaded onto 3730 DNA Analyzer together 
with GeneScan 500 Liz Size Standard following the manufacturer’s instructions. 
Analysis was performed by GeneMapper v.3.5 and peak parameters were evaluated by 
Peak Scanner (Applied Biosystems, Foster City, CA, USA).  
 
Denaturing High Performance Liquid Chromatography 
WAVE 208 Nucleic Acid Fragment Analysis System (Transgenomic, Omaha, NE) was 
applied for the mutant load evaluation with DHPLC. PCR reaction was performed with 
AmpliTaq gold polymerase (Applied Biosystems, Foster City, CA, USA) using a 
forward and reverse primers and the amplification product was separated using 61,1ºC 
separation temperature (Kurelac et al, 2011).   
 
RNA extraction and Real Time analysis  
RNA was extracted from snap-frozen tissues with RNeasy Plus Mini kit (Qiagen, 
Milan, Italy) and cDNA was prepared using SuperScript III Reverse Transcriptase 
(Invitrogen, Milan, Italy) following manufacturers’ instructions. Expression of GLUT-1, 
VEGF-A and LDHA was analyzed with Real Time PCR using Sybr Green chemistry and 
7500 Fast Real Time System (Applied Biosystems) as previously described (Gasparre et 
al, 2011).  
 
Statistics  
SigmaStat 3.5 software was used for statistical analysis applying Student’s t-test unless 
otherwise indicated. 
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Allotopic MTND1 expression strategy 
Human mitochondrial MTND1 gene was nucleus-recoded and engineered in p3XFLAG-
CMV-14 vector in the Laboratorio di Genetica Medica (Sant’Orsola Hospital, Bologna). 
To optimize the efficiency of allotopic expression, the ND1 mRNA was targeted to the 
mitochondrial surface, thus ensuring tight coupling between both translation and 
translocation processes of the highly hydrophobic corresponding polypeptide. To 
achieve that, the engineered ND1 gene was combined with the cis-acting elements of the 
COX10 gene, which ensures the efficient sorting of the mRNAs to the mitochondrial 
surface (Sylvestre J. et al., 2003; Bonnet C. et al., 2007; Bonnet C. et al., 2008). Hence, 
the MTS (mitochondrial targeting sequence) and COX10 3’ UTR (untranslated region) 
were added in frame at the N- and C-terminal of the protein, respectively (Fig.11). 
Moreover, a FLAG epitope was appended at the C-terminal. 
                                       
                         
                                      Figure 11. Schematic ND1 construct. 
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Allotopic ND1 expression restores the energetic efficiency in cells bearing 
m.3571insC ND1 mutation 
The ND1 construct was transfected in OS-93 osteosarcoma cybrid line, bearing 
homoplasmic m.3571insC MTND1 mutation. This frame-shift mutation causes the 
translation of a truncated ND1 protein, which is subsequently degraded and induces 
complex I disassembly. Therefore, due to the lack of respiratory chain complex I, OS-93 
cell line is characterized by a severe energetic impairment (Porcelli AM et al., 2010).  
After transfection, ten stable cell lines were isolated by antibiotic selection and then 
incubated in a glucose-free medium containing galactose, in order to select those cells 
with an efficient oxidative phosphorylation, resulting from successful restoration of 
complex I function/assembly. Two cell clones, OS-93ND1-B and OS-93ND1-C, were 
significantly more viable in galactose medium than OS-93, suggesting their capacity to 
rely solely on oxidative phosphorylation for energy production (Fig. 12). Conversely, 
we previously demonstrated that OS-93 cells are unable to grow in galactose medium, 
(Porcelli AM et al. 2010). 
The precise MTND1 mutation load was measured by fluorescent PCR (Kurelac I. et al., 
2011), in collaboration with the Laboratorio di Genetica Medica. The MTND1 mutation 
was virtually homoplasmic in OS-93 and OS-93ND1-B, whereas the OS-93ND1-C clone 
was a revertant (Fig.13), and therefore it was excluded by further analysis.  Moreover, 
by sequencing the whole gene, clone was repeatedly confirmed not to accumulate 
additional MTND1 mutations that may complement the m.3571insC for example via the 
recovery of the reading frame. 
In order to verify that ND1 protein was translated and imported into mitochondria, 
Western blot analysis was performed on control (CC), OS-93 and OS-93ND1 cybrid 
clones. The ND1 protein was detected in the mitochondrial fraction from CC and OS-
93ND1 only (Fig.14A), clearly indicating successful allotopic expression. Moreover, to 
assess whether the complex I assembly was restored in OS-93ND1 cybrid clone, 
mitochondria were separated by 2D BN/SDS PAGE, further processed by western blot 
and incubated with antibody against ND1 (Fig. 14B) and the nuclear subunit NDUFV1 
(Fig. 14C). Both subunits were detected in OS-93ND1 in the fully assembled complex I. 
The complex I function was then determined by the in-gel activity (IGA) assay. As 
shown in Fig. 14D, the complex I IGA was fully restored upon ND1 allotopic 
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expression. Finally, the rate of rotenone-sensitive ATP synthesis was markedly 
increased in OS-93ND1, clearly indicating that complex I function was recovered 
(Fig.15). Conversely, no difference in complex II-driven synthesis was observed, 
suggesting that the effect of allotopic expression was specific for complex I (Fig.15).  
 
 
 
                           
                        
 
 
              
 
Figura 12. Viability in galactose medium. The cell lines were incubated in DMEM containing galactose 
for indicated times and viability was determined by SRB assay. Data represents the media ± SEM (n=4) 
and statistics was defined by STUDENT t-test (p<0,05). 
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         Figura 13. ND1 mutation heteroplasmy level measured by DHPLC and fluorescent PCR. 
 
 
 
 
 
Figura 14. Complex I subunits content and in-gel activity (IGA) of isolated mitochondria fractions. A) 
Western blot for ND1 protein in CC (cybrid control), OS-93 and OS-93ND1. VDAC was used as a 
mitochondrial loading control. Western blot analysis of complex I assembly using ND1 (B) and NDUFV1 
(C) antibodies, respectively. D)  Complex I IGA assay on CC, OS-93 and OS-93ND1.  
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Figura 15. Mitochondrial ATP synthesis by complex I (upper) and by complex II (bottom) was 
determined in digitonin-permeabilized cells in presence of pyruvate/malate and succinate, respectively. 
Rates, normalized by citrate synthase (CS) activity of corresponding sample, are mean (n=4) ± SD. 
 
 
 
 
ND1 allotopic expression rescues tumorigenic potential of OS-93 cell line 
 
We previously demonstrated that m.3571insC MTND1 in OS-93 cells hampers tumor 
growth in vivo due to the complex I disassembly and consequent HIF1α destabilization 
(Gasparre et al., 2011). 
To assess if the in vivo tumorigenic potential of OS-93 cells was rescued by ND1 
allotopic expression and complex I assembly/function recovery, we injected OS-93 and 
OS-93ND1 in nude mice. OS-93ND1-derived tumors grew significantly larger than OS-93-
derived ones (Fig. 16A).  
No other mutation was detected in xenografts upon re-sequencing the whole mtDNA 
apart from m.3571insC MTND1. Complex I IGA was detected only in xenografts 
derived from OS-93ND1 cells but not in OS-93 derived tumor. These results clearly 
demonstrate that complex I assembly and function are required to increase tumorigenic 
potential in vivo.  
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Complex I recovery by ND1 allotopic expression hampers oncocytic 
transformation 
 
The m.3571insC MTND1 is a hallmark of oncocytic lesions together with similar 
truncating mutations mainly occurring in homoplasmy (Bonora et al., 2007; Porcelli et 
al., 2010). We demonstrated that this mutation is sufficient to induce oncocytic 
transformation when above threshold (disassembled complex I), but not when below 
threshold (complex I is properly assembled and able to cope with tumor energetic 
requirements) (Gasparre et al., 2011).  
Then we verified whether an inactive and disassembled complex I was required for 
oncocytic transformation. Indeed, electron microscopy analysis showed increased 
mitochondria number and swollen morphology (Fig.17) on xenograft of OS-93, that is 
typical of  an oncocytic look. These data therefore confirmed that the presence of a 
functioning complex I hampers oncocytic transformation. 
 
 
                                          
 
 
 
 
 
 
 
                                     
                              
Figura 16. A. Tumor growth generated by injection of  OS
means of two experiments each 
93ND1 derived xenografts after explant (OST, OS tumor). One representative experiment of four is 
showed. 
 
 
 
                            
  
 
                  
Figura 17. Electron microscopy on xenografts after explants. (4) and (11) indicate mouse
number. Oncocytic phenotype is apparent 
mitochondria morphology and disorganized cristae
present in allotopic tumors, whose OST
 
 
 
-93 and OS-93ND1 in nude mice. Data are 
with 5 animals ± SEM; *, P<0,01. B. Complex I IGA
in OS-93(4) tumor by increased mitochondria number, swollen 
 (arrows indicate some examples)
-93ND1(11) is a representative case.  
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Hif1α-stabilization is involved in incresead tumor growth  
 
In order to assess whether the increase of tumorigenic potential of OS-93ND1 in vivo 
requires HIF1α stabilization tumor growth, immunohistochemistry analysis was 
performed on xenografts. Staining of MTND6 complex I subunit and HIF1α was 
positive only in OS-93ND1-derived tumors, whereas it was negative in OS-93-derived 
one (Fig. 18A) indicating a strong association between HIF1α and MTND6 expression 
(Fig.18B). As we previously showed, HIF1α destabilization due to the complex I 
disassembly, is associated to an imbalance of the TCA α-ketoglutarate (αKG) and 
succinate  intermediates (Porcelli et al., 2010; Gasparre et al., 2011). This imbalance 
favours accumulation of the first one, thus increasing the ratio αKG/succinate, 
promoting  HIF1α-hydroxilation by PHD and consequently causing its proteosomic 
degradation. To verify whether this imbalance was reverted by ND1 in vivo allotopic 
expression, the αKG/SA ratio was determined after metabolites extraction from 
xenografts and measurement by mass spectrometry. αKG/SA ratio was significantly 
higher in OS-93 xenograft compared to OS-93ND1 ones (Fig. 18C), demonstrating that 
the balance of these TCA cycle metabolites depends on proper activity of complex I. 
Besides, to evaluate whether HIF1α stabilization in OS-93ND1 tumors could have 
induced some functional consequences on downstream gene expression, the  expression 
of its responsive genes was determined. An increased expression of glucose transporter-
1 (GLUT1), vascular endothelial growth factor A (VEGFA) and lactate dehydrogenase 
A (LDHA) was detected in these tumors only (Fig.19A). Moreover, staining with 
hypoxic marker pimonidazole (Chen Y. et al., 2009) showed some greater hypoxic areas 
in OS93-derived small tumor in comparison to that OS93ND1 derived larger ones 
(Fig.19B), highlighting that HIF1α stabilization was prevented in complex I deficient 
tumors, despite to a real hypoxic condition.  
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Biochemical effect of ND1 allotopic expression is also preserved in ex vivo cell lines 
 
To point out and further verify ND1 allotopic expression effect, additional analysis has 
been made also in ex vivo cell lines. Cell lines were isolated from single very small OS-
93 derived xenograft, namely OSC-93(4), and from the four largest OS-93ND1 
xenografts, namely OSC-93ND1(11), (12), (17) and (19). It was verified by F-PCR that 
they were not revertants and then they were biochemically analyzed. During incubation 
in galactose medium, the cell viability was significantly lower for OSC-93(4) compared 
to OSC-93ND1(11), (12), (17) and (19) (Fig. 20A), whereas western blot experiments  
showed ND1 protein presence only in mitochondrial fraction of  OSC-93ND1(11), (12), 
(17),  (19) (Fig. 20B). Unfortunately, cyclic heteroplasmy level measuring by F-PCR 
showed that OSC-93ND1(17) and (19) was turned into revertants, probably due to a 
mutation shift versus wild type occurred during cell growth in medium culture. For this 
reason, they were not considered for further analysis. Instead, OSC-93(4), OSC-
93ND1(11) and OSC-93ND1(12) cell lines were analyzed by 2D BN/SDS PAGE and by 
IGA experiments to verify that ND1 allotopic protein was correctly inserted in complex 
I. Figure 21 shows that complex I was assembled and active in OSC-93ND1(11) and 
OSC-93ND1(12) but not in OSC-93(4), demonstrating that allotopic expression was 
maintained also in ex-vivo cell lines.  
                      
Figura 18. Recovery of complex I assembly implicates Hif1
Representative IHC staining using antibodies against MTND6 and Hif1
dissected tumor masses and (B) linear regression from overall data. C. The ratio of 
calculated by measuring the level of each metaboli
 
 
                                         
 
Figura 19. A. Gene expression levels of Hif1
OS-93ND1 xenografts. Absolute mRNA quantification of GLUT
explanted from nude mice is reported (*, P<0,05; **, P<0,01). Black bars indicate the average value. B. 
Pimonidazole staining of OS-93 and representative OS
α stabilization in OS-93
α on OS
α
te from 3 different experiments of mass spectrometry.
 
α-responding genes observed in OS-93 and representative 
-1, VEGF-A, and LDHA in tumors 
-93ND1 tumors. Magnification x63.
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Figura 20. A. Viability in galactose medium of ex vivo OS-93 and OS-93ND1 cell lines. The cell lines 
isolated from xenograft after explants, were incubated in DMEM containing galactose for indicated times 
and viability was determined by SRB assay. Data represents media ± SEM (n=4) and statistics was 
defined by ANOVA (p<0,001). B. Western Blot analysis for ND1 on mitochondrial fraction of ex vivo 
OSC-93 and OSC-93ND1 cell lines. VDAC was used as mitochondrial loading control.   
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Figura 21. A. Complex I IGA assay on ex-vivo cells OSC-93(4), and OSC-93ND1(11) and (12) isolated 
mitochondria. B. C. Western blot analysis of complex I assembly using ND1 and NDUFV1 antibodies, 
respectively. Antibody against NDUFV1 nuclear subunit showed the correct CI assembly in OSC-
93ND1(11) and in OSC-93ND1(12), whereas part of the peripheral arm is accumulated in small molecular 
weight sub-assembled in OSC-93(4) (indicated with red triangle). 
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In the present study we achieved two important goals, in relation to the applied strategy 
and to the experimental results. Allotopic expression strategy was improved and further 
optimized in last decade with the aim to perfect a possible gene therapy for 
mitochondrial diseases by biochemical defect complementation. Despite this strategy 
has been successfully demonstrated in yeast, in mammalian mitochondria results are 
very controversial. In fact, available evidence is based only on partial phenotype rescue, 
and not on the demonstrated incorporation of a functional protein into respiratory 
complexes. Indeed, this apparent functional complementation has been shown also 
depend on selection of revertant mtDNA genomes (Perales-Clemente et al., 2010). 
Among all, the main critical issue for the allotopic strategy is certainly the difficult and 
inefficient mitochondrial import of such highly hydrophobic proteins (Oca-Cossio J. et 
al., 2003). 
In this study, we undertook a different approach to solve the issue of feasibility of the 
allotopic strategy for gene therapy of mtDNA mutations and to assess its efficiency in 
truly complementing the biochemical dysfunction. We took advantage of the previously 
characterized cybrid cell models harboring the homoplasmic disruptive m.3571insC 
MTND1 mutation shown to induce complex I disassembly in vitro and in vivo (Gasparre 
at al., 2011). In order to complement the homoplasmic m.3571insC, causing translation 
of truncated protein thereafter degraded, we recoded MTND1 for cytosolic translation 
(nND1) by adapting codon usage via in vitro site-directed mutagenesis. The eukaryotic 
expression construct was generated with the aim to facilitate nND1 mRNA targeting to 
the external mitochondrial membrane according to Bonnet and co-workers (Bonnet et 
al., 2007). The 5’UTR containing a MTS of nuclear coded COX10 mitochondrial 
subunit of  complex IV was cloned upstream of and in frame with nND1, while 3’UTR 
of COX10 was cloned downstream. Previously used vectors with a built-in MTS, in 
fact, are not suitable as they are designed for matrix soluble, not for membrane 
embedded proteins. After transfection of the construct in our cybrid model OS-93, 
knocked for ND1, and after following selection of virtually positive clones by antibiotic 
and by galactose medium, we addressed the issue of genetic revertants. Sensitivity of 
Sanger sequencing was not sufficient to exclude low levels of wild-type mtDNA copies, 
as the threshold for phenotypic effect of disruptive mutations has been shown by us to 
be quite high (Gasparre et al., 2011). Therefore, for the first time we here implemented 
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a previously optimized combination of methods for the detection of low levels of 
m.3571insC (Kurelac I. et al., 2011), an analysis that has lacked so far, in the attempt to 
ascertain the mutation reversion (Perales-Clemente et al., 2010). We obtained the 
precise load of mutant mtDNA by fluorescent PCR and confirmed it by denaturing high 
performance liquid chromatography in the selected clones, discriminating a revertant 
one (not further considered) and a positive allotopic one. First, we detected correct 
synthesis and import to mitochondria of nND1 protein exclusively in allotopic positive 
clone OS-93ND1, by Western blot analysis on mitochondrial fraction, using a specific 
ND1 antibody. Moreover, in order to verify that the nND1 subunit was assembled 
within complex I, we performed a two-dimensional Blue Native SDS-PAGE followed 
by western blotting and specific immunodetection of complex I subunits. nND1 
immunoreactivity was associated with the fully assembled complex I in the positive 
control (CC), whereas no immunoreactivity was observed in OS-93; finally, the anti-
ND1 in the OS-93ND1 showed the presence of the subunit in the fully assembled 
complex. Further confirmation of the recovery of complex I assembly came from the 
incubation with the anti-NDUFV1 nuclear subunit antibody, which immunoreactivity 
was associated with the fully assembled complex I in the positive control whereas in the 
OS-93 the NDUFV1 subunit was present in the monomeric form and in the small 
subcomplex, but not in the fully assembled complex I. Finally, NDUFV1 in OS-93ND1 
was present in the monomeric form, in the subcomplex and also in the fully assembled 
complex. Moreover, complex I IGA band, detected exclusively in CC and in OS-93ND1, 
but not in OS-93, proved that nND1 restored not only complex I assembly, but also its 
enzymatic activity and this was further confirmed by measurement of rotenone-sensitive 
ATP synthesis. 
These results provide solid evidence that allotopic expression of ND1 led to its import 
within mitochondria and, more importantly, allowed for re-expression of assembled 
complex I, which could not occur with the native mutant ND1 subunit, being truncated, 
degraded and for this reason not expressed. Furthemore, by sequencing the whole gene, 
cell lines were repeatedly confirmed not to accumulate additional MTND1 mutations 
that may complement the m.3571insC e.g. via the recovery of the reading frame. 
Moreover, the necessary exclusion that the re-assembled complex I might have occurred 
because of low, under the detection-level amounts of revertant wild-type mtDNA was 
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reasonably achieved by the implemented sensitive approach for heteroplasmy detection 
(Kurelac I et al., 2011). 
These results offer promising expectations because, finally demonstrating without 
ambiguity that allotopic strategy is feasible and effective in correcting the OXPHOS 
defects due to mtDNA mutations, they represent a first step for a future clinical trial in 
patients. Furthermore, despite the limited efficiency of mitochondrial import of the 
allotopically expressed protein, low levels of heteroplasmy are known to be sufficient to 
complement the OXPHOS deficiency due to mutant mtDNA (Park and Larsson, 2011); 
thus, easily accessible tissues, as it is the case, for example, for retinal ganglion cells in 
Leber’s Hereditary Optic Neuropathy (LHON), are potentially suitable to the allotopic 
strategy using safe and efficient vectors.    
The second important goal of the present study arises from the results of OS-93 and OS-
93ND1 cell lines injection in nude mice. We have previously demonstrated that 
m.3571insC, following a threshold effect, hampers in vivo tumor growth of cancer cells. 
Indeed, we identified a precise threshold for such mutation, sufficient to increase the α-
KG/SA ratio, thus inducing  HIF1α destabilization,  and ultimately  triggering growth 
arrest. We previously provided the proof of principle regarding the antitumorigenic 
effect of a mtDNA truncating mutation by using our unique cell model (Porcelli et al., 
2010) and then experimentally reinforced that through reinjection of highly isogenic 
clones OSC-78 and OSC-83, carrying a mutation load below and above threshold, 
respectively. In agreement with our previous observations in patients  with oncocytic 
tumors (Porcelli et al., 2010), tumor xenografts bearing a mutation above threshold 
displayed pseudo-normoxia, showing HIF1α destabilization despite being truly hypoxic. 
We have shown that this mechanism, tightly linked to the α-KG/SA imbalance as it 
occurs in SDH and FH mutated tumors but in opposite direction, may be sufficient to 
drive the tumor into a "blind alley" due to both respiratory impairment and lack of 
HIF1α-dependent glycolysis induction (Gasparre et al., 2011b). Accumulation of 
NADH and inhibition of α-ketoglutarate dehydrogenase are likely the most plausible 
mechanisms for the α-KG/SA ratio increase as a consequence of complex I disassembly. 
This imbalance in the TCA cycle intermediates may hence either boost the PHD affinity 
for molecular oxygen or diminish the availability of the main allosteric inhibitor of 
PHD, that is SA, thus determining HIF1α destabilization even during hypoxia.  
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The most important consideration come from the strong association between 
homoplasmic disassembling mtDNA mutations, such as the m.3571insC by us 
investigated in the present study, and the mostly benign oncocytic tumor phenotype. 
Patients with oncocytic tumors (epithelial derived tumors) rarely present highly 
aggressive, metastatic cancers; in the majority of cases, these tumors are surgically 
removed because of hindrance at the site of occurrence. Our findings provide an 
explanation for this clinical observation through HIF1α destabilization, strictly 
correlated to complex I disassembly and, in turn, lack of activation of downstream 
pathways activation implicated in glycolytic metabolic shift (Warburg effect) and 
angiogenesis. Our studies in mice have shown that, upon trespassing the threshold, the 
mutation is sufficient to trigger oncocytic transformation even in a nonepithelial cancer, 
highlighting the importance of homoplasmy  of  disruptive mtDNA  mutation  as  
prognostic  markers.  
Obtaining an allotopic positive clone, in which complex I assembly and function were 
restored by complementation of m.3571insC with wild-type nND1 expression, has 
given us the unique opportunity to further confirm these important previous results. We 
expected to observe the rescue of tumorigenic potential of OS-93 cell line after 
expression of nND1 protein, as a consequence of complex I re-assembly and function. 
Accordingly, injection of two cell lines OS-93 and OS-93ND1 in nude mice displayed the 
rescue of tumor growth for the allotopic one only, in which complex I was fully 
assembled and active, as confirmed also by the CI-IGA assay on xenografts. Moreover, 
electron microscopy did not show oncocytic phenotype in OS-93ND1–derived 
xenografts, confirming that functioning complex I hampers oncocytic transformation. 
As expected, HIF1α was shown stabilized by IHC in OS-93ND1-derived xenografts, and 
this was confirmed also by a lower αKG/SA ratio and by down-regulation of its 
responsive genes (LDHA, VEGF, GLUT1). In addition, we showed that allotopic 
expression of ND1 was preserved also in cell lines isolated from OS-93ND1-derived 
xenografts, such as its incorporation in a functioning complex I.  
Taken together, these results provide unambiguous and further evidence about the role 
of complex I in the tumorigenesis process, due to its close relation with HIF, which is 
considered one of the master regulators of the metabolic adaptation needed for cancer 
cells to progress to malignancy. Furthermore, a few important implications stem from 
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these results, concerning some possible clinical applications, arising, for example, from 
the translation of a genetic into a metabolic shift of the α-KG/SA ratio toward α-KG, 
which supports the use of cell-permeable α-KG derivatives in anticancer therapy 
(MacKenzie et al., 2007). Other strategies may impinge on induction of complex I 
disassembly in patients not harboring mtDNA mutations, degradation of assembly 
factors, or even modulation of mitochondrial biogenesis to induce both the mutation and 
its accumulation. Moreover, induction of oncocytic transformation could be envisioned 
as an approach to reduce tumor growth and abolish aggressive and metastatic potential.  
Our hope is that the results achieved in this study from allotopic strategy and its in vivo 
applications, can open new effective perspectives on clinical therapy of deseases caused 
by mtDNA mutations, both degenerative deseases and tumors.  
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